Venous Thromboembolism

Thrombosis rates among patients with systemic lupus erythematosus decrease 13% for every increase of 200 ng/mL in mean hydroxychloroquine in the blood, according to data presented at the EULAR 2020 virtual congress.

TNF inhibitors bested conventional disease-modifying antirheumatic drugs at reducing venous thromboembolic events in patients with rheumatoid arthritis, according to data presented at the EULAR 2020 E-Congress.

Thromboprophylaxis with low-molecular-weight heparin alone appeared noninferior to thromboprophylaxis combined with graduated compression stockings for individuals at moderate or high risk for venous thromboembolism after elective surgery, according to results of a randomized study published in BMJ.

Given the novelty of COVID-19 and a lack of scientific evidence, many clinicians treating critically ill patients with the disease, particularly those with acute respiratory distress syndrome, have been using conventional supportive care strategies and mechanical ventilation. Questions have emerged, however, about whether other treatments may also prove beneficial in this patient population.

Patients who underwent spine surgery for treatment of metastases had a high risk of developing both symptomatic and fatal pulmonary embolism, according to results.

Low-dose rivaroxaban (Xarelto, Bayer/Janssen) twice daily plus aspirin vs. placebo plus aspirin in PAD.

Patients treated with PCSK9 inhibitors had reduced risk for venous thromboembolism, especially if they had elevated lipoprotein(a), according to findings presented at the virtual American College of Cardiology Scientific Session.

Treatment with rivaroxaban was more effective than enoxaparin for preventing venous thromboembolism during immobilization after lower-limb nonmajor orthopedic surgery, according to results of the PRONOMOS trial.

Treatment of venous thromboembolism with oral apixaban was noninferior to subcutaneous dalteparin, without increasing major bleeding risk, according to results from the CARAVAGGIO trial presented at the virtual American College of Cardiology Scientific Session.

Deep Vein Thrombosis Awareness Month is observed every March.